Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Ann N Y Acad Sci. 2018 Jan;1412(1):154–165. doi: 10.1111/nyas.13535

Figure 3.

Figure 3

Summary of MuSK cell-based assay data performed with plasmablast-derived monoclonal antibodies (mAbs). Results are presented as Δ% positive (for MuSK binding) cells on the y-axis. Δ% positive cells = (% frequency of positive MuSK–GFP–transfected cells/% frequency of MuSK–GFP–transfected cells) – (% frequency of positive GFP–transfected cells/% frequency of GFP–transfected cells). Bars represent means, and dots represent individual mAb values. Testing of all samples was performed in duplicate. Plasmablast-derived mAb from MuSK MG post-rituximab relapse patients MuSK 1 (n = 4), MuSK 2b (n = 33), MuSK 3 (n = 45) and AChR control patients AChR 7 (n = 15) and AChR 8 (n = 11) are shown. The 4A3 mAb is a humanized, murine hybridoma–derived MuSK-specific mAb that was used as a positive control. The dotted line represents the Δ% positive cells cutoff (control mean + 4SD = 21.9). Adapted from Ref. 38.